Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA in stage I, II, and III germ cell tumors

Diagnostic study collecting serial ctDNA in high-risk stage I, stage II, and stage III germ cell tumors to estimate positive predictive value for relapse, retroperitoneal histology, and progression after chemotherapy.

Indiana University